We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
Global Investment in Vaccines R&D (2014)
HIV Vaccine Research: An Update
A quick, colorful and comprehensive overview of HIV vaccine research. Four pages, five top-line updates, this is a speedy read, designed to give a sense of the momentum and major issues coming up in the year to come.
Second European HIV Prevention Summit Meeting Report
In January 2016, the European AIDS Treatment Group (EATG) and AVAC jointly convened the second European HIV Prevention Summit in Brussels. This meeting brought pharmaceutical companies, public health experts, academics and leading scientists in the field of prevention research together with over 50 European community-based advocates for three days of information exchange and debate. The four-page executive summary is attached. The meeting agenda and slide presentations from the meeting are available for download at http://eatgavacprevention.tumblr.com.
Px Wire April-June 2016, Vol. 9, No. 2
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue is an advocate’s guide to the past, present and future of the dapivirine ring for HIV prevention. Featuring a timeline of key milestones that could lead to licensure, a simple comprehensive Q & A, and a closer look at where sub-Saharan African women will have access to daily oral PrEP and/or the Ring via open-label extension studies.
Patchwork of Prevention for Women: Oral PrEP and the Dapivirine Ring
Participants in the ring efficacy studies will get extended access to the ring via open-label studies. But will they have access to PrEP? This map shows which sites will provide PrEP and which will not. Excerpted from Px Wire.
Dapivirine Ring Results—A snapshot
This infographic provides detailed study design and result information from The Ring Study (IPM 027) and ASPIRE (MTN-020). The lower portion of the infographic charts additional, related studies and the regulatory process before the ring’s earliest possible introduction. Excerpted from Px Wire.
Harnessing Antibodies for HIV Prevention and Treatment
John Mascola of the NIH Vaccine Research Center spoke about harnessing antibodies for HIV prevention and treatment. The recording includes discussion with webinar participants. For more background, click here to view his CROI plenary session.
Evidence for HIV Prevention Options
What’s the big picture of ARV-based prevention trial results? This graphic shows the levels of efficacy from each major trial (that’s the square icon) with the confidence intervals around the finding (the bars at either side). Not sure what a confidence interval is? See our one-page Advocates’ Guide to Statistical Terms. For PDF and JPEG versions, please click here.
ASPIRE and The Ring Study Results — A Snapshot
Results from two Phase III multi-country trials (ASPIRE and Ring) studying the 4-week slow-release dapivirine vaginal ring were released at the 2016 Conference on Retroviruses and Opportunistic Infection. This chart details study design and enrollment, gives overall results and breaks results down by age.
Px Wire January-March 2016, Vol. 9, No. 1
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. In this issue we survey the year ahead and write about what to watch for in 2016. In our centerspread we update our timeline of biomedical HIV prevention research.